JP2015503552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503552A5 JP2015503552A5 JP2014550009A JP2014550009A JP2015503552A5 JP 2015503552 A5 JP2015503552 A5 JP 2015503552A5 JP 2014550009 A JP2014550009 A JP 2014550009A JP 2014550009 A JP2014550009 A JP 2014550009A JP 2015503552 A5 JP2015503552 A5 JP 2015503552A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- disease
- pyridin
- imidazo
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 230000003463 hyperproliferative effect Effects 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 102000006500 Janus Kinase 3 Human genes 0.000 claims 2
- 108010019421 Janus Kinase 3 Proteins 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 102100039079 Tyrosine-protein kinase TXK Human genes 0.000 claims 2
- 101710101516 Tyrosine-protein kinase TXK Proteins 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- CVMLLVMHCHSTAM-UHFFFAOYSA-N 4-[6-chloro-7-[3-(prop-2-enoylamino)phenoxy]-1h-imidazo[4,5-b]pyridin-2-yl]-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C1=NC2=NC=C(Cl)C(OC=3C=C(NC(=O)C=C)C=CC=3)=C2N1 CVMLLVMHCHSTAM-UHFFFAOYSA-N 0.000 claims 1
- IPPTWUDURFOTCR-UHFFFAOYSA-N 4-[6-chloro-7-[3-(prop-2-enoylamino)phenoxy]-1h-imidazo[4,5-b]pyridin-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=NC2=NC=C(Cl)C(OC=3C=C(NC(=O)C=C)C=CC=3)=C2N1 IPPTWUDURFOTCR-UHFFFAOYSA-N 0.000 claims 1
- -1 7- (3-acrylamidophenoxy) -6-chloro-3H-imidazo [4,5-b] pyridin-2-yl Chemical group 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010052613 Allergic bronchitis Diseases 0.000 claims 1
- 206010049153 Allergic sinusitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000013059 antihormonal agent Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 229940046731 calcineurin inhibitors Drugs 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000000138 intercalating agent Substances 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- GYPBAOUSZINBKE-UHFFFAOYSA-N n-[3-[(6-chloro-2-pyridin-4-yl-1h-imidazo[4,5-b]pyridin-7-yl)oxy]phenyl]prop-2-enamide Chemical compound ClC1=CN=C2N=C(C=3C=CN=CC=3)NC2=C1OC1=CC=CC(NC(=O)C=C)=C1 GYPBAOUSZINBKE-UHFFFAOYSA-N 0.000 claims 1
- KRDXNACYXWVAJV-UHFFFAOYSA-N n-[3-[[2-[4-(4-methylpiperazin-1-yl)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2NC3=C(OC=4C=C(NC(=O)C=C)C=CC=4)C=CN=C3N=2)C=C1 KRDXNACYXWVAJV-UHFFFAOYSA-N 0.000 claims 1
- KUSHEIGLDZTAIC-UHFFFAOYSA-N n-[3-[[6-chloro-2-(4-methoxyphenyl)-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C1=NC2=NC=C(Cl)C(OC=3C=C(NC(=O)C=C)C=CC=3)=C2N1 KUSHEIGLDZTAIC-UHFFFAOYSA-N 0.000 claims 1
- WULMWOJVBYRVKA-UHFFFAOYSA-N n-[3-[[6-chloro-2-(4-methylsulfinylphenyl)-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC2=NC=C(Cl)C(OC=3C=C(NC(=O)C=C)C=CC=3)=C2N1 WULMWOJVBYRVKA-UHFFFAOYSA-N 0.000 claims 1
- YBUZITOKAPMLST-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-(4-hydroxypiperidin-1-yl)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CC(O)CCN1C1=CC=C(C=2NC3=C(OC=4C=C(NC(=O)C=C)C=CC=4)C(Cl)=CN=C3N=2)C=C1 YBUZITOKAPMLST-UHFFFAOYSA-N 0.000 claims 1
- MOTJOHGREQRUBI-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-(4-methylpiperazin-1-yl)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2NC3=C(OC=4C=C(NC(=O)C=C)C=CC=4)C(Cl)=CN=C3N=2)C=C1 MOTJOHGREQRUBI-UHFFFAOYSA-N 0.000 claims 1
- SUWHXDHAQLNXDS-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-(4-methylpiperazine-1-carbonyl)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2NC3=C(OC=4C=C(NC(=O)C=C)C=CC=4)C(Cl)=CN=C3N=2)C=C1 SUWHXDHAQLNXDS-UHFFFAOYSA-N 0.000 claims 1
- QAHNGWCWXWTYQA-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-(diethylaminomethyl)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1=CC(CN(CC)CC)=CC=C1C1=NC2=NC=C(Cl)C(OC=3C=C(NC(=O)C=C)C=CC=3)=C2N1 QAHNGWCWXWTYQA-UHFFFAOYSA-N 0.000 claims 1
- ZMYMAWLVJDFSJL-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-(dimethylamino)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=C(Cl)C(OC=3C=C(NC(=O)C=C)C=CC=3)=C2N1 ZMYMAWLVJDFSJL-UHFFFAOYSA-N 0.000 claims 1
- CBUUIDYECPJOTM-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-(morpholin-4-ylmethyl)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound ClC1=CN=C2N=C(C=3C=CC(CN4CCOCC4)=CC=3)NC2=C1OC1=CC=CC(NC(=O)C=C)=C1 CBUUIDYECPJOTM-UHFFFAOYSA-N 0.000 claims 1
- ZVTQUHLELHTHAJ-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-(morpholine-4-carbonyl)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound ClC1=CN=C2N=C(C=3C=CC(=CC=3)C(=O)N3CCOCC3)NC2=C1OC1=CC=CC(NC(=O)C=C)=C1 ZVTQUHLELHTHAJ-UHFFFAOYSA-N 0.000 claims 1
- CNBLTNYIXNTCJW-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-(piperidin-1-ylmethyl)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound ClC1=CN=C2N=C(C=3C=CC(CN4CCCCC4)=CC=3)NC2=C1OC1=CC=CC(NC(=O)C=C)=C1 CNBLTNYIXNTCJW-UHFFFAOYSA-N 0.000 claims 1
- GBSMHQQWSWEVGL-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-(pyrrolidin-1-ylmethyl)phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound ClC1=CN=C2N=C(C=3C=CC(CN4CCCC4)=CC=3)NC2=C1OC1=CC=CC(NC(=O)C=C)=C1 GBSMHQQWSWEVGL-UHFFFAOYSA-N 0.000 claims 1
- SINQCZHHCNQXKN-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-[(1-methylpiperidin-4-yl)amino]phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCC1NC1=CC=C(C=2NC3=C(OC=4C=C(NC(=O)C=C)C=CC=4)C(Cl)=CN=C3N=2)C=C1 SINQCZHHCNQXKN-UHFFFAOYSA-N 0.000 claims 1
- KWPRURVJPUKYLO-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1CC1=CC=C(C=2NC3=C(OC=4C=C(NC(=O)C=C)C=CC=4)C(Cl)=CN=C3N=2)C=C1 KWPRURVJPUKYLO-UHFFFAOYSA-N 0.000 claims 1
- RRTYJYSEFVWILG-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-[(dimethylamino)methyl]phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1=CC(CN(C)C)=CC=C1C1=NC2=NC=C(Cl)C(OC=3C=C(NC(=O)C=C)C=CC=3)=C2N1 RRTYJYSEFVWILG-UHFFFAOYSA-N 0.000 claims 1
- HVVWVMXMCBSDOA-UHFFFAOYSA-N n-[3-[[6-chloro-2-[4-[[ethyl(methyl)amino]methyl]phenyl]-1h-imidazo[4,5-b]pyridin-7-yl]oxy]phenyl]prop-2-enamide Chemical compound C1=CC(CN(C)CC)=CC=C1C1=NC2=NC=C(Cl)C(OC=3C=C(NC(=O)C=C)C=CC=3)=C2N1 HVVWVMXMCBSDOA-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110144450A KR20130076046A (ko) | 2011-12-28 | 2011-12-28 | 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체 |
| KR10-2011-0144450 | 2011-12-28 | ||
| PCT/KR2012/011570 WO2013100631A1 (en) | 2011-12-28 | 2012-12-27 | Novel imidazopyridine derivatives as a tyrosine kinase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015503552A JP2015503552A (ja) | 2015-02-02 |
| JP2015503552A5 true JP2015503552A5 (https=) | 2016-02-12 |
Family
ID=48697977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014550009A Ceased JP2015503552A (ja) | 2011-12-28 | 2012-12-27 | チロシンキナーゼ阻害剤としての新規イミダゾピリジン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150299185A1 (https=) |
| EP (1) | EP2797909A4 (https=) |
| JP (1) | JP2015503552A (https=) |
| KR (1) | KR20130076046A (https=) |
| CN (1) | CN104024243A (https=) |
| AU (1) | AU2012363557A1 (https=) |
| BR (1) | BR112014016146A8 (https=) |
| CA (1) | CA2859664A1 (https=) |
| HK (1) | HK1200811A1 (https=) |
| IL (1) | IL233415A0 (https=) |
| MX (1) | MX2014007976A (https=) |
| RU (1) | RU2014131068A (https=) |
| WO (1) | WO2013100631A1 (https=) |
| ZA (1) | ZA201405505B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105837572B (zh) * | 2015-02-02 | 2019-04-19 | 四川大学 | N-取代苯基酰胺衍生物及其制备方法和用途 |
| CN109563092B (zh) * | 2016-07-11 | 2021-09-14 | 坎塞拉有限公司 | 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物 |
| MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| CA3141571A1 (en) * | 2019-05-28 | 2020-12-03 | Mankind Pharma Ltd. | 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN116854687B (zh) * | 2021-03-23 | 2025-07-25 | 杭州阿诺生物医药科技有限公司 | Hpk1激酶抑制剂化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE70593B1 (en) * | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO1999016755A1 (en) * | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| US20090170847A1 (en) * | 2006-01-23 | 2009-07-02 | Seung Chul Lee | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same |
| BRPI0707245A2 (pt) * | 2006-01-23 | 2011-04-26 | Crystalgenomics Inc | derivados de imidazopiridina que inibem a atividade de proteìna quinase, método para a preparação destes e composição farmacêutica contendo os mesmos |
| IL295053A (en) * | 2007-03-28 | 2022-09-01 | Pharmacyclics Llc | Broton tyrosine kinase inhibitors |
| US20100113520A1 (en) * | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| KR101483215B1 (ko) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| PT2585470T (pt) * | 2010-06-23 | 2017-03-06 | Hanmi Science Co Ltd | Novos derivados fundidos de pirimidina para inibição da actividade da tirosina cinase |
| CN102827186A (zh) * | 2011-06-16 | 2012-12-19 | 中国科学院上海药物研究所 | 一类吡啶并五元杂环衍生物及其制备方法和用途 |
-
2011
- 2011-12-28 KR KR1020110144450A patent/KR20130076046A/ko not_active Withdrawn
-
2012
- 2012-12-27 HK HK15101096.4A patent/HK1200811A1/xx unknown
- 2012-12-27 WO PCT/KR2012/011570 patent/WO2013100631A1/en not_active Ceased
- 2012-12-27 BR BR112014016146A patent/BR112014016146A8/pt not_active IP Right Cessation
- 2012-12-27 AU AU2012363557A patent/AU2012363557A1/en not_active Abandoned
- 2012-12-27 CA CA2859664A patent/CA2859664A1/en not_active Abandoned
- 2012-12-27 JP JP2014550009A patent/JP2015503552A/ja not_active Ceased
- 2012-12-27 RU RU2014131068A patent/RU2014131068A/ru not_active Application Discontinuation
- 2012-12-27 CN CN201280064532.0A patent/CN104024243A/zh active Pending
- 2012-12-27 MX MX2014007976A patent/MX2014007976A/es unknown
- 2012-12-27 EP EP12861996.2A patent/EP2797909A4/en not_active Withdrawn
- 2012-12-27 US US14/368,702 patent/US20150299185A1/en not_active Abandoned
-
2014
- 2014-06-26 IL IL233415A patent/IL233415A0/en unknown
- 2014-07-25 ZA ZA2014/05505A patent/ZA201405505B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503552A5 (https=) | ||
| EP3768667B1 (en) | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| JP7187308B2 (ja) | Ｄｎａ損傷剤とａｔｒ阻害剤との組み合わせを使用する、がんを処置するための方法 | |
| RU2014147193A (ru) | Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности | |
| ES2557281T3 (es) | Compuestos amida, composiciones y usos de los mismos | |
| JP6726773B2 (ja) | 新規な４−アミノピラゾロ［３，４−ｄ］ピリミジニルアザビシクロ誘導体およびこれを含む薬学組成物 | |
| JP2013529179A5 (https=) | ||
| JP2022110080A (ja) | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法 | |
| US9382226B2 (en) | Aldosterone synthase inhibitors | |
| JP6517790B2 (ja) | ４−アザインドール誘導体 | |
| JP2017515844A5 (https=) | ||
| JP2023523418A (ja) | Ｎｌｒｐ３の阻害剤としての三環式化合物 | |
| IL301690A (en) | Piperidinyl small molecule degraders of helios and methods of use | |
| JP2013528204A5 (https=) | ||
| JP2014506599A5 (https=) | ||
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| JP2011520832A5 (https=) | ||
| JP2016540803A5 (https=) | ||
| RU2014131068A (ru) | Новые производные имидазопиридина в качестве ингибиторов тирозинкиназы | |
| JP2013525356A5 (https=) | ||
| JP2013523814A5 (https=) | ||
| CA2989722A1 (en) | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy | |
| US9567333B2 (en) | Triazolopyridyl compounds as aldosterone synthase inhibitors | |
| KR20190002468A (ko) | N-[2-(3-히드록시-3-메틸부틸)-6-(2-히드록시프로판-2-일)-2h-인다졸-5-일]-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 결정질 형태 | |
| WO2020010003A1 (en) | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |